10 Best Income Stocks to Invest in Now

5. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 85

AbbVie Inc. (NYSE:ABBV) is an American pharmaceutical company that focuses on research and innovation, developing and marketing treatments for a range of chronic and serious health conditions.

AbbVie Inc. (NYSE:ABBV) reported strong earnings in the first quarter of 2025. The company posted revenue of $13.3 billion, which saw an 8.3% growth from the same period last year and also beat analysts’ estimates by $422 million. The company’s immunology division continued to perform strongly, with Skyrizi and Rinvoq delivering enough growth to offset the expected drop in Humira sales. Solid results were also seen in the neuroscience and oncology segments, with Elahere standing out by bringing in $179 million in global revenue. A major driver of this success was the positive outcome of the MIRASOL trial, where Elahere showed a clear advantage over chemotherapy in treating ovarian cancer, cutting the risk of death by 32% and the risk of disease progression or death by 37%.

AbbVie Inc. (NYSE:ABBV) is solidifying its reputation as an active acquirer through several recent deals. These include the purchase of ImmunoGen to gain control of Elahere, the acquisition of Nimble Therapeutics to expand its autoimmune pipeline, and a licensing agreement with Gubra focused on obesity treatments—a competitive space currently led by Eli Lilly and Novo Nordisk.

AbbVie Inc. (NYSE:ABBV), one of the best dividend stocks, currently offers a quarterly dividend of $1.64 per share for a dividend yield of 3.55%, as of May 9. The company has been growing its dividend payouts for 52 consecutive years.